Inhibition of lipoprotein secretion
US7517860B1 · kind B1 · utility
0Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 21, 2000 |
| Grant date | Apr 14, 2009 |
| Priority date | — |
| Expiry date | Jul 21, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It has been discovered that the low density lipoprotein receptor (LDLR) degrades the lipoprotein apoB. Based on this observation, an artificial fusion protein has been designed containing an LDL receptor domain attached to a localization domain which causes retention of the fusion protein inside of a cell. The fusion protein is preferably retained in the endoplasmic reticulum of the cell, where the LDLR can degrade apoB. Data shows that the technique is effective in a mammal to reduce serum LDL cholesterol levels.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.